Heinz Hammerlindl
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Heinz Hammerlindl has a total of 42 co-authors. Here are the top co-authors by number of shared publications:
- Lani F. Wu
Department of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, USA
3 shared publications - Steven J. Altschuler
Department of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, USA
3 shared publications Li Li
Department of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, USA
2 shared publicationsSabrina Hammerlindl
Department of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, USA
2 shared publicationsSusan Q. Shen
Department of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, USA
2 shared publications- Alexander B. Chase
Department of Earth Sciences. Southern Methodist University, Dallas, TX, USA
1 shared publication
Latest Publications
- Open Access
- 7 September 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Programmable CAR-engaging particles rewire human CAR T-cell signaling for sustainable ex vivo expansion
T cell proliferative capacity and persistence determine the therapeutic efficacy of chimeric antigen receptor (CAR) T cells. However, strategies to externally enhance CAR-T cell expansion without genetic rewiring are lacking. Here, we engineer CAREp, programmable DNA-scaffolded PLGA microparticles displaying CAR-targeting antigens and CD28-costimulatory antibodies, to repeatedly stimulate human CD8+ CAR-T cells ex vivo. CAREp sustains a-EGFR CAR-T cell expansion for over 100 days across both 4-1BBζ and CD28ζ constructs, achieving up to 1018-fold cumulative expansion and surpassing tumor-cell or CD3/CD28-Dynabeads stimulation. Expanded cells retain effector function and mitochondrial fitness while exhibiting clonal enrichment, initially preserved memory-associated progenitor states, delayed exhaustion, and transiently activated telomerase delaying telomere attrition. Early transcriptomic responses show coordinated activation of DNA repair, chromatin remodeling, telomere maintenance, and mitochondrial function while restricting differentiation-associated signaling programs, mirroring long-term functional outcomes. These findings demonstrate that nanoscale ligand organization synchronizes acute CAR-T signaling with durable proliferative and metabolic states.
- 7 September 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessProgrammable CAR-engaging particles rewire human CAR T-cell signaling for sustainable ex vivo expansion
T cell proliferative capacity and persistence determine the therapeutic efficacy of chimeric antigen receptor (CAR) T cells. However, strategies to externally enhance CAR-T cell expansion without genetic rewiring are lacking. Here, we engineer CAREp, programmable DNA-scaffolded PLGA microparticles displaying CAR-targeting antigens and CD28-costimulatory antibodies, to repeatedly stimulate human CD8+ CAR-T cells ex vivo. CAREp sustains a-EGFR CAR-T cell expansion for over 100 days across both 4-1BBζ and CD28ζ constructs, achieving up to 1018-fold cumulative expansion and surpassing tumor-cell or CD3/CD28-Dynabeads stimulation. Expanded cells retain effector function and mitochondrial fitness while exhibiting clonal enrichment, initially preserved memory-associated progenitor states, delayed exhaustion, and transiently activated telomerase delaying telomere attrition. Early transcriptomic responses show coordinated activation of DNA repair, chromatin remodeling, telomere maintenance, and mitochondrial function while restricting differentiation-associated signaling programs, mirroring long-term functional outcomes. These findings demonstrate that nanoscale ligand organization synchronizes acute CAR-T signaling with durable proliferative and metabolic states.
- 11 July 2025
- Published by Springer Nature in Nature Biotechnology
- Vol. 44 (5) , 862-872
Transitive prediction of small-molecule function through alignment of high-content screening resources
High-content image-based phenotypic screens (HCSs) provide a scalable approach to characterize biological functions of compounds. The widespread adoption of HCS has led to a growing body of available profile datasets. However, study-specific experimental and computational choices lead to profile datasets that cannot be directly combined. A critical, long-standing challenge is how to integrate these rich but currently isolated HCS dataset resources. Here we introduce a contrastive, deep-learning framework that leverages sparse sets of overlapping profiles as fiducials to align heterogeneous HCS profile datasets in a shared latent space. We demonstrate that this alignment facilitates accurate ‘transitive’ predictions, whereby the function of an uncharacterized compound screened in one dataset can be predicted through comparison with characterized compounds already profiled in other datasets. In silico alignment of HCS resources provides a path to unify fast-growing HCS resources and accelerate early drug discovery efforts.
- 11 July 2025
- Published by Springer Nature in Nature Biotechnology
- Vol. 44 (5) , 862-872
Transitive prediction of small-molecule function through alignment of high-content screening resources
High-content image-based phenotypic screens (HCSs) provide a scalable approach to characterize biological functions of compounds. The widespread adoption of HCS has led to a growing body of available profile datasets. However, study-specific experimental and computational choices lead to profile datasets that cannot be directly combined. A critical, long-standing challenge is how to integrate these rich but currently isolated HCS dataset resources. Here we introduce a contrastive, deep-learning framework that leverages sparse sets of overlapping profiles as fiducials to align heterogeneous HCS profile datasets in a shared latent space. We demonstrate that this alignment facilitates accurate ‘transitive’ predictions, whereby the function of an uncharacterized compound screened in one dataset can be predicted through comparison with characterized compounds already profiled in other datasets. In silico alignment of HCS resources provides a path to unify fast-growing HCS resources and accelerate early drug discovery efforts.
- Open Access
- 18 March 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-13
A phenopushing platform to identify compounds that alleviate acute hypoxic stress by fast-tracking cellular adaptation
Severe acute hypoxic stress is a major contributor to the pathology of human diseases, including ischemic disorders. Current treatments focus on managing consequences of hypoxia, with few addressing cellular adaptation to low-oxygen environments. Here, we investigate whether accelerating hypoxia adaptation could provide a strategy to alleviate acute hypoxic stress. We develop a high-content phenotypic screening platform to identify compounds that fast-track adaptation to hypoxic stress. Our platform captures a high-dimensional phenotypic hypoxia response trajectory consisting of normoxic, acutely stressed, and chronically adapted cell states. Leveraging this trajectory, we identify compounds that phenotypically shift cells from the acutely stressed state towards the adapted state, revealing mTOR/PI3K or BET inhibition as strategies to induce this phenotypic shift. Importantly, our compound hits promote the survival of liver cells exposed to ischemia-like stress, and rescue cardiomyocytes from hypoxic stress. Our “phenopushing” platform offers a general, target-agnostic approach to identify compounds and targets that accelerate cellular adaptation, applicable across various stress conditions.
- 18 March 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-13
Open AccessA phenopushing platform to identify compounds that alleviate acute hypoxic stress by fast-tracking cellular adaptation
Severe acute hypoxic stress is a major contributor to the pathology of human diseases, including ischemic disorders. Current treatments focus on managing consequences of hypoxia, with few addressing cellular adaptation to low-oxygen environments. Here, we investigate whether accelerating hypoxia adaptation could provide a strategy to alleviate acute hypoxic stress. We develop a high-content phenotypic screening platform to identify compounds that fast-track adaptation to hypoxic stress. Our platform captures a high-dimensional phenotypic hypoxia response trajectory consisting of normoxic, acutely stressed, and chronically adapted cell states. Leveraging this trajectory, we identify compounds that phenotypically shift cells from the acutely stressed state towards the adapted state, revealing mTOR/PI3K or BET inhibition as strategies to induce this phenotypic shift. Importantly, our compound hits promote the survival of liver cells exposed to ischemia-like stress, and rescue cardiomyocytes from hypoxic stress. Our “phenopushing” platform offers a general, target-agnostic approach to identify compounds and targets that accelerate cellular adaptation, applicable across various stress conditions.
- Open Access
- 19 June 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-14
Small molecule in situ resin capture provides a compound first approach to natural product discovery
Culture-based microbial natural product discovery strategies fail to realize the extraordinary biosynthetic potential detected across earth’s microbiomes. Here we introduce Small Molecule In situ Resin Capture (SMIRC), a culture-independent method to obtain natural products directly from the environments in which they are produced. We use SMIRC to capture numerous compounds including two new carbon skeletons that were characterized using NMR and contain structural features that are, to the best of our knowledge, unprecedented among natural products. Applications across diverse marine habitats reveal biome-specific metabolomic signatures and levels of chemical diversity in concordance with sequence-based predictions. Expanded deployments, in situ cultivation, and metagenomics facilitate compound discovery, enhance yields, and link compounds to candidate producing organisms, although microbial community complexity creates challenges for the later. This compound-first approach to natural product discovery provides access to poorly explored chemical space and has implications for drug discovery and the detection of chemically mediated biotic interactions.
- 19 June 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-14
Open AccessSmall molecule in situ resin capture provides a compound first approach to natural product discovery
Culture-based microbial natural product discovery strategies fail to realize the extraordinary biosynthetic potential detected across earth’s microbiomes. Here we introduce Small Molecule In situ Resin Capture (SMIRC), a culture-independent method to obtain natural products directly from the environments in which they are produced. We use SMIRC to capture numerous compounds including two new carbon skeletons that were characterized using NMR and contain structural features that are, to the best of our knowledge, unprecedented among natural products. Applications across diverse marine habitats reveal biome-specific metabolomic signatures and levels of chemical diversity in concordance with sequence-based predictions. Expanded deployments, in situ cultivation, and metagenomics facilitate compound discovery, enhance yields, and link compounds to candidate producing organisms, although microbial community complexity creates challenges for the later. This compound-first approach to natural product discovery provides access to poorly explored chemical space and has implications for drug discovery and the detection of chemically mediated biotic interactions.
- Open Access
Membrane-active peptides escape drug-resistance in cancer
Acquired drug-resistance is a recurring problem in cancer treatment, and this is particularly true for patients with metastatic melanoma that carry a BRAF V600E mutation. In the current study, we explored the use of membrane-active peptides as an alternative therapeutic modality to target drug-resistant melanoma cells. We produced slow-cycling and drug-resistant melanoma cells using dabrafenib, a small molecule drug that targets tumor cells with BRAF V600E mutation, and characterised their lipidome and proteome to investigate the role of membrane lipids in acquired drug-resistance. Despite some changes in the lipid composition, tested anti-melanoma membrane-active cyclic peptides (cTI and cGm) killed melanoma cells that are sensitive, tolerant, or resistant to dabrafenib. Importantly, melanoma cells did not develop resistance to cTI or cGm, nor changed their lipid composition with long-term peptide treatment. Therefore, these peptides are well suited as templates to design therapeutic leads to target drug-resistant metastatic melanoma cells and/or as co-treatment with small molecule drugs.
Open AccessMembrane-active peptides escape drug-resistance in cancer
Acquired drug-resistance is a recurring problem in cancer treatment, and this is particularly true for patients with metastatic melanoma that carry a BRAF V600E mutation. In the current study, we explored the use of membrane-active peptides as an alternative therapeutic modality to target drug-resistant melanoma cells. We produced slow-cycling and drug-resistant melanoma cells using dabrafenib, a small molecule drug that targets tumor cells with BRAF V600E mutation, and characterised their lipidome and proteome to investigate the role of membrane lipids in acquired drug-resistance. Despite some changes in the lipid composition, tested anti-melanoma membrane-active cyclic peptides (cTI and cGm) killed melanoma cells that are sensitive, tolerant, or resistant to dabrafenib. Importantly, melanoma cells did not develop resistance to cTI or cGm, nor changed their lipid composition with long-term peptide treatment. Therefore, these peptides are well suited as templates to design therapeutic leads to target drug-resistant metastatic melanoma cells and/or as co-treatment with small molecule drugs.
- 29 January 2020
- Published by University of Queensland Library
Characterizing therapy induced adaptive phenotypic plasticity leading to acquired drug resistance in cancer
The University of Queensland's institutional repository, UQ eSpace, aims to create global visibility and accessibility of UQ’s scholarly research.
- 29 January 2020
- Published by University of Queensland Library
Characterizing therapy induced adaptive phenotypic plasticity leading to acquired drug resistance in cancer
The University of Queensland's institutional repository, UQ eSpace, aims to create global visibility and accessibility of UQ’s scholarly research.